Therapy Detail

Therapy Name TAS-116
Therapy Description

TAS-116 is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TAS-116 HSP90 Inhibitor 35 TAS-116 is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable TAS-116 Phase I Actionable In a Phase I trial, TAS-116 treatment resulted in partial response in 6% (3/47) and stable disease in 26% (12/47) of patients with advanced solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2546)). detail...
Unknown unknown gastrointestinal stromal tumor not applicable TAS-116 Phase I Actionable In a Phase I trial, TAS-116 treatment resulted in partial response in a patient with gastrointestinal stromal tumor (J Clin Oncol 35, 2017 (suppl; abstr 2546)). detail...
Unknown unknown non-small cell lung carcinoma not applicable TAS-116 Phase I Actionable In a Phase I trial, TAS-116 treatment resulted in partial response in 2 patients with non-small cell lung carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 2546)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Recruiting